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ABSTRACT
A multicentre study involving seven laboratories was performed using techniques recommended by the
Antifungal Susceptibility Testing Subcommittee of the European Committee on Antimicrobial Suscepti-
bility Testing (AFST-EUCAST) to evaluate and propose quality control ranges and strains for
susceptibility testing of fermentative yeasts and ﬁlamentous fungi. Participating laboratories tested the
susceptibilities of a panel of 12 encoded isolates to amphotericin B, ﬂucytosine, ﬂuconazole, itraconazole,
voriconazole and posaconazole. In total, 15 lots of assay mediumwere tested, with one lot being common
to all laboratories, and 18 144 MIC values were determined. Intra- and inter-laboratory agreements and
intra-class correlation coefﬁcients (ICCs) of the results for each drug ⁄ strain ⁄ lot combination were
calculated. An average value of 85% agreement was selected for validation purposes. The average
percentage of intra-laboratory agreement was 90–95%, with ICC values of 0.90–0.95 (p <0.01). Inter-
laboratory reproducibility was also high, with 92% agreement and an ICC of 0.97 (p <0.01). The
reproducibility was somewhat better with the common lot of assay medium (96% agreement) than with
the different lots (91% agreement), but this difference was not signiﬁcant. Two isolates that showed
trailing growth had agreement percentages below the 85% limit selected for validation purposes andwere
therefore excluded from the panel of quality control strains. The recommended EUCAST methodologies
were found to be highly reproducible and reliable for susceptibility testing of yeasts and ﬁlamentous
fungi. Ten isolates are proposed for use as quality control strains with these EUCAST procedures.
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INTRODUCTION
The European Committee on Antimicrobial
Susceptibility Testing (EUCAST) is a standing
committee organised jointly by the European
Society of Clinical Microbiology and Infectious
Diseases (ESCMID) and European national break-
point committees. EUCAST was set up to
standardise antimicrobial breakpoints and
susceptibility testing methods in Europe. Formed
in 1996 and restructured in 2002, EUCAST has a
Subcommittee on Antifungal Susceptibility Test-
ing (AFST-EUCAST) that aims to standardise
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methodology and determine breakpoints for anti-
fungal drugs [1].
AFST-EUCAST has recommended a standard
broth microdilution method for the determination
of MICs for fermentative species of yeasts
(http://www.escmid.org/Files/E_Def_7-1_06-2002.
pdf). Several surveys have demonstrated that this
standard is a reproducible method which pro-
duces results comparable to those obtained using
the reference M27-A2 procedure recommended
by the CLSI [2–8].
AFST-EUCAST has also recommended a broth
dilution method for the determination of MICs for
ﬁlamentous fungi [9]. This method is based on the
reference method recommended by the CLSI for
antifungal susceptibility testing of ﬁlamentous
fungi (document M38-A) [10], but includes
several modiﬁcations, such as the use of RPMI
2% G (see below) as the assay medium, the
preparation of the inoculum by conidium count-
ing in a haemacytometer, and the use of an
inoculum size of 1 · 105 - 5 · 105 CFU ⁄mL
[11–15]. It has been demonstrated previously that
the CLSI and EUCAST methods produce compa-
rable results for ﬁlamentous fungi [16]. The
present report describes a multicentre study,
involving seven laboratories, that aimed to iden-
tify quality control (QC) strains of yeasts and
ﬁlamentous fungi, and to determine QC ranges
for susceptibility testing of six antifungal agents
according to the EUCAST methodology.
MATERIALS AND METHODS
Strains
Participants tested a panel of 12 encoded isolates. Table 1
shows the strains that were selected for the study, based on
their on-scale and varied MICs of antifungal agents, as
determined in preliminary surveys (data not shown).
Antifungal agents
Amphotericin B (lot no. 13204147; Fluka, Sigma-Aldrich
Quı´mica, Madrid, Spain), ﬂucytosine (lot no. S01804-493;
Sigma-Aldrich Quı´mica), ﬂuconazole (batch no. 02FLU0-010-
00; Pﬁzer, Sandwich, UK), itraconazole (batch no.
ZR051211PUJ621; Janssen Pharmaceutica, Beerse, Belgium),
voriconazole (batch no. 109496-0R2-25; Pﬁzer) and posaconaz-
ole (batch no. IRQ-56592-02-X-GM1; Schering-Plough, Kenil-
worth, NJ, USA) were obtained directly from the respective
manufacturers as reagent grade powders. The powders were
stored as recommended by the manufacturers at the Spanish
National Centre for Microbiology. Aliquots (100 mg) of these
antifungal agents were sent to each participating laboratory,
together with an indication of the potency of each drug.
Dilutions were prepared in appropriate solvents according to
EUCAST recommendations [5,9]
Assay medium
The assay medium used in the study was RPMI-1640 without
sodium bicarbonate and with L-glutamine, buffered to pH 7.0
with 0.165 M morpholinepropanesulphonic acid, and supple-
mented with glucose 18 g ⁄L to reach a ﬁnal concentration of
2% w ⁄v (referred to as RPMI 2% G medium). Each partici-
pating laboratory used three lots of medium: a common lot
supplied by the Spanish National Centre for Microbiology (lot
no. QCbatch1-15022005; Sigma-Aldrich Quı´mica), and two lots
that were obtained and prepared individually by each partic-
ipating laboratory. Thus, in total, 15 different lots of medium
were tested during the study. Culture medium was prepared
as a double-strength solution and was ﬁlter-sterilised using a
0.22-lm ﬁlter.
Susceptibility testing
The methodology used adhered strictly to the recommended
standards of EUCAST for the determination of MICs for
fermentative species of yeasts and for ﬁlamentous fungi [5,9].
Susceptibility testing was performed in triplicate on two
separate occasions for each lot of RPMI 2% G, with each run
using fresh isolates and microtitration trays. Yeast isolates
were incubated in ambient air at 35–37C on recovery medium
(Sabouraud’s dextrose agar or peptone dextrose agar) for
18–24 h before testing. Moulds were subcultured at 35C on
potato dextrose agar slants or other culture media on which
each fungus was able to sporulate properly. Mould inoculum
suspensions were prepared from fresh, mature cultures (aged
2–5 days). Sterile plastic microtitration plates with ﬂat-bot-
tomed wells (Corning Costar Europe, Badhoevedorp, The
Netherlands) were used. Each participating laboratory pre-
pared its own trays. The plates contained two-fold serial
dilutions of each antifungal drug (100 lL ⁄well). Two wells
containing drug-free medium were used for sterility and
growth controls. Trays were inoculated with 100 lL ⁄well of
Table 1. Agreement rates and intra-class correlation
coefﬁcients (ICCs) with statistical signiﬁcance per isolate
tested
Strain Identiﬁcation
Agreement
(%)a ICC p
ATCC 6258 Candida krusei 89.6 0.96 <0.01
ATCC 22019 Candida parapsilosis 91.6 0.92 <0.01
CNM-CL-4815 Candida albicans 93.2 0.98 <0.01
CNM-CL-4818 Candida glabrata 81.2 0.82 <0.01
CNM-CL-3780 Candida tropicalis 83.6 0.81 <0.01
CNM-CL-3403 Candida krusei 91.2 0.96 <0.01
ATCC 204305 Aspergillus fumigatus 96.2 0.91 <0.01
ATCC 204304 Aspergillus ﬂavus 95.2 0.91 <0.01
CNM-CM-237 Aspergillus fumigatus 93.7 0.85 <0.01
CNM-CM-2159 Aspergillus fumigatus 95.4 0.99 <0.01
CNM-CM-2524 Aspergillus terreus 91.0 0.86 <0.01
CNM-CM-1813 Aspergillus ﬂavus 93.5 0.85 <0.01
ATCC, American Type Culture Collection; CNM-CL, Spanish National Centre for
Microbiology, Yeast Culture Collection; CNM-CM, Spanish National Centre for
Microbiology, Filamentous Fungi Culture Collection.
aA value of 85% was selected to validate the exercise. Rates of agreement and ICCs
are calculated from the results obtained by all participants for all drugs and lots of
medium.
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the ﬁnal inoculum. Final concentrations of drugs were:
amphotericin B, 0.03–16.0 mg ⁄L; ﬂucytosine and ﬂuconazole,
0.12–64.0 mg ⁄L; and itraconazole, voriconazole and posaco-
nazole, 0.015–8.0 mg ⁄L. The microdilution plates were incu-
bated at 35C for 48 h, with MICs being determined after 24 h
and 48 h.
Statistical analysis
The seven participating laboratories reported 36 MIC values
for each antifungal agent for each strain. Thus, 2592 MIC
values were included in the survey from each participating
laboratory, giving a total of 18 144 MIC values for analysis. In
order to validate the exercise, intra- and inter-laboratory
agreement of the results for each drug ⁄ strain ⁄ lot combination
were calculated. A level of 85% average agreement was
selected for validation purposes. Agreement was deﬁned as
the percentage of MIC results within one two-fold dilution
interval of the mode. Intra-laboratory agreement was calcu-
lated using the 36 MIC values obtained by each participating
laboratory for each drug ⁄ strain ⁄ lot combination. Inter-labora-
tory agreement was evaluated by calculating the concordance
among the MIC values determined by the participating
laboratories and the mode MIC among the replicate results
from the participants (252 MIC values for each antifungal
agent and strain combination). Differences in proportions were
determined by Fisher’s exact test or by chi-square analysis, as
appropriate.
Intra-class correlation coefﬁcients (ICCs) were also calcu-
lated. These coefﬁcients compared the results of the MIC
determinations transformed on log2 data for the 12 strains.
A two-way random effect model with a 95% CI was used to
calculate the ICCs. The ICC is a reverse measurement of the
variability of MIC values that evaluates the correlation
between values offering statistical signiﬁcance, since it takes
into account the number of cases and the absolute MIC
values. The ICC was calculated using the formula
ICC = (group mean square minus error mean square) divided
by (group mean square plus error mean square), and
therefore has a maximum value of 1 if there is a perfect
correlation, and a minimum value of )1 if there is a complete
absence of correlation.
QC limits were deﬁned as MIC ranges that included one
doubling concentration on either side of the mode. When two
adjacent concentrations displayed similar frequencies, the
mode was assumed to be somewhere between the even log2
concentrations that were tested, and a four-dilution range was
proposed [17].
A p value of <0.01 was considered signiﬁcant. Both on-scale
and off-scale results were included in the analysis. The low off-
scale MICs were left unchanged, while the high off-scale MICs
were converted to the next highest concentration. All statistical
analyses were performed using SPSS v.14.0 (SPSS, Madrid,
Spain).
RESULTS
The average percentage of intra-laboratory agree-
ment for the seven participating laboratories was
90–95%, with ICC values of 0.90–0.95 (p <0.01).
No signiﬁcant differences were found when the
results were analysed according to the lot of assay
medium, the strain or the antifungal agent being
tested, with rates of agreement >90% and ICC
values >0.90. Inter-laboratory reproducibility was
also high, with 92% agreement and an ICC of 0.97
(p <0.01). The reproducibility was somewhat
better for results obtained with the common lot
of assay medium (96% agreement) than with the
different lots (91% agreement), but this difference
was not signiﬁcant.
When analysed according to each antifungal
agent, the highest reproducibility values were
observed for ﬂuconazole and voriconazole (94%
and 91% agreement and ICCs of 0.95 and 0.92,
respectively; p <0.01). Agreement for amphoter-
icin B, ﬂucytosine and posaconazole was >85%,
with statistically signiﬁcant ICCs. Lower but
signiﬁcant reproducibility was observed for
itraconazole (81% agreement and an ICC of
0.85).
When analysed according to strain (Table 1),
agreement rates were >85% (i.e., the limit selected
for validation purposes), apart from Candida
glabrata CNM-CL-4818 and Candida tropicalis
CNM-CL-3780 (81% and 83% agreement, respec-
tively). ICC values for each strain ranged between
0.81 and 0.99 (p <0.01).
Table 2 summarises the control limit ranges
and percentage of MIC values falling within the
range for each strain and for each antifungal
agent, as reported by the seven participating
laboratories. QC ranges were calculated with
readings after 24 h for yeast isolates and after
48 h for moulds [5,9]. Two strains exhibiting
<85% agreement, i.e., CNM-CL-4818 and CNM-
CL-3780, were excluded from the QC panel and
their ranges are not shown in Table 2.
DISCUSSION
This collaborative survey was performed to
evaluate and propose QC ranges and strains
for susceptibility testing of fermentative yeasts
and ﬁlamentous fungi according to the methods
recommended by AFST-EUCAST [5,9]. The
results of this seven-laboratory multicentre study
indicate that the technique for determination of
MICs for fermentative yeasts and the method for
susceptibility testing of ﬁlamentous fungi are both
very reproducible, with high percentages of intra-
and inter-laboratory agreements, and high ICCs.
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A value of ‡85% average agreement was selected
to validate the exercise, but average inter-labora-
tory agreement was 92%. In addition, the corre-
lation coefﬁcients obtained were statistically
signiﬁcant (0.97, p <0.01). Notably, the reproduc-
ibility among participants was comparable,
regardless of the precise lot of assay medium
used.
Reproducibility was lower in some cases when
results were analysed according to antifungal
agent or isolate. The reproducibility of itraconazole
MICs was lower than those of other antifungal
agents. Itraconazole is a lipophilic drug that is
insoluble in water, and which must therefore be
diluted in an appropriate non-aqueous solvent
such as dimethylsulphoxazole. In order to pre-
pare working solutions, susceptibility testing
standards recommend a series of dilutions from
a stock solution of an antifungal agent in the same
solvent in order to avoid dilution artefacts that
result from precipitation of compound. However,
obtaining homogeneous solutions of itraconazole
is not straightforward, and this can have a
signiﬁcant effect on the reproducibility of MIC
results [9]. The relative inﬂuence of different test
variables on itraconazole MICs, and the fact that
each fungal isolate can respond differently to
combinations of variables in the test, have been
demonstrated previously [18].
Two strains, C. glabrata CNM-CL-4818 and
C. tropicalis CNM-CL-3780, had percentages of
agreement below the 85% limit selected for
validation purposes, and were therefore
excluded from the panel of QC strains. Both of
these strains showed signiﬁcant trailing growth,
so that the MICs after incubation for 24 h were
much lower than those after 48 h. It could be
argued, as in previous studies [5,8], that trailing
growth can be an important source of variability
and inaccuracy in MIC determinations. The other
ten strains showed high reproducibility and
correlation indices, and are therefore proposed
for use as QC strains in conjunction with
EUCAST procedures, particularly the ATCC
strains, which are readily available in clinical
laboratories interested in antifungal susceptibil-
ity testing. It should be noted that the QC ranges
for Candida krusei ATCC 6258 and Candida
parapsilosis ATCC 22019 are one or two two-fold
dilutions lower than those recommended by the
CLSI [17]. As reported previously [6,7], MICs
obtained using EUCAST procedures are consis-
tently lower than those obtained using the
methods recommended by the CLSI. This differ-
ence is believed to be associated with the
incubation time, since the recommended incuba-
tion time is 24 h for the EUCAST procedure and
48 h for the CLSI method. Accordingly, QC
ranges obtained using CLSI methods should
not be used to validate MICs obtained using
the EUCAST procedures. The QC ranges shown
in Table 2 provide clinical and research labora-
tories with guidance for ensuring the quality of
the susceptibility testing results obtained using
EUCAST procedures.
Table 2. Control limit ranges and percentage of MIC
values within the range for each proposed quality control
strain and antifungal agent
Strain Identiﬁcation
Antifungal
agenta
Control limit
range (mg ⁄L)
% MIC values
in the range
ATCC 6258 Candida
krusei
Amphotericin B 0.12–1.0 91.6
Flucytosine 1.0–4.0 95.8
Fluconazole 16.0–64.0 88.9
Itraconazole 0.03–0.12 87.5
Voriconazole 0.03–0.25 87.5
Posaconazole 0.015–0.06 86.1
ATCC 22019 Candida
parapsilosis
Amphotericin B 0.12–1.0 86.1
Flucytosine 0.12–0.50 97.2
Fluconazole 0.50–2.0 94.4
Itraconazole 0.03–0.12 86.1
Voriconazole 0.015–0.06 100
Posaconazole 0.015–0.06 86.1
CNM-CL-4815 Candida
albicans
Amphotericin B 0.06–0.50 86.3
Flucytosine 0.06–0.25 100
Fluconazole 32.0 to >64.0 97.2
Itraconazole 0.25–1.0 90.7
Voriconazole 0.50–2.0 94.4
Posaconazole 0.12–0.50 90.7
CNM-CL-3403 Candida
krusei
Amphotericin B 0.25–1.0 89.8
Flucytosine 2.0–8.0 91.7
Fluconazole 16.0–64.0 100
Itraconazole 0.12–0.50 92.6
Voriconazole 0.12–0.50 88.1
Posaconazole 0.06–0.25 85.2
ATCC 204305 Aspergillus
fumigatus
Amphotericin B 0.25–1.0 100
Itraconazole 0.12–0.50 100
Voriconazole 0.25–1.0 94.4
Posaconazole 0.03–0.25 90.3
ATCC 204304 Aspergillus
ﬂavus
Amphotericin B 0.50–2.0 97.2
Itraconazole 0.12–0.50 100
Voriconazole 0.50–2.0 91.7
Posaconazole 0.12–0.50 91.7
CNM-CM-237 Aspergillus
fumigatus
Amphotericin B 0.25–1.0 99.1
Itraconazole 0.12–0.50 96.3
Voriconazole 0.25–1.0 91.6
Posaconazole 0.015–0.25 88.0
CNM-CM-2159 Aspergillus
fumigatus
Amphotericin B 0.25–1.0 87.1
Itraconazole 8.0 to >16.0 98.1
Voriconazole 0.50–2.0 96.3
Posaconazole 0.50–2.0 100
CNM-CM-2524 Aspergillus
terreus
Amphotericin B 1.0–8.0 90.7
Itraconazole 0.12–0.50 86.2
Voriconazole 0.50–2.0 100
Posaconazole 0.06–0.25 87.1
CNM-CM-1813 Aspergillus
ﬂavus
Amphotericin B 1.0–4.0 91.7
Itraconazole 0.12–0.50 100
Voriconazole 0.50–2.0 97.2
Posaconazole 0.12–0.50 85.3
ATCC, American Type Culture Collection; CNM-CL, Spanish National Center for
Microbiology, Yeast Culture Collection; CNM-CM, Spanish National Center for
Microbiology, Filamentous Fungi Culture Collection.
aMIC ranges of ﬂucytosine or ﬂuconazole for ﬁlamentous fungi are not displayed in
the table because these MICs were invariably >64 mg ⁄L.
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